Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Innate Pharma SA

< Previous 1 2 3 4 5 Next >
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Transformative Strategy to Accelerate Growth
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Releases Its 2025 Financial Calendar
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports First Half 2024 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Outcome of Innate Pharma’s 2024 Annual General Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.